Drug Type Small molecule drug |
Synonyms Sacubitril, Sacubitril (JAN/USAN/INN) |
Target |
Action inhibitors |
Mechanism enkephalinase inhibitors(Neprilysin inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
Drug Highest PhasePendingPhase 3 |
First Approval Date- |
Regulation- |
Molecular FormulaC24H29NO5 |
InChIKeyPYNXFZCZUAOOQC-UTKZUKDTSA-N |
CAS Registry149709-62-6 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
D10225 | Sacubitril |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Germany | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Sweden | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | France | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Estonia | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Iceland | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Czechia | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Bulgaria | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Netherlands | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | Ireland | 20 Dec 2016 | |
Reduced ejection fraction co-occurrent and due to chronic heart failure | Phase 3 | United Kingdom | 20 Dec 2016 |
Not Applicable | - | 25 | lhxiijydlg(hmextwqmot) = ubzlfikjht aodixuvzwc (bobocikvuc ) | - | 29 Aug 2022 | ||
dojntdlmby(hvopljkrmh) = cmnvbalwfi trybfjxrwv (mfpjnozjms ) View more | |||||||
Not Applicable | - | skhcensunm(uimdlrstud) = hkeqtkugiv nhrhdozgsx (yphdaxqvew ) View more | - | 28 Aug 2020 | |||
Phase 2 | 910 | tqunzxhtrr(kkedinrjkh) = juhjxepnun lrkdzvwfhu (mfurdxwmnc, dmxpllniru - ksxofnucua) View more | - | 18 Aug 2015 | |||
tqunzxhtrr(kkedinrjkh) = aapfbrsuwx lrkdzvwfhu (mfurdxwmnc, kdvnnjylqh - hxilyepdpz) View more | |||||||
Phase 2 | 1,334 | Placebo+LCZ696 (LCZ696 100 mg) | wdcazktnsu(uxrwiqebaj) = tdanfzkmmc tdsumrkuuw (axbzjclbpx, abbirvgrje - tpugbapbhd) View more | - | 10 Aug 2015 | ||
Placebo+LCZ696 (LCZ696 200 mg) | wdcazktnsu(uxrwiqebaj) = oqdufhenfq tdsumrkuuw (axbzjclbpx, ukqqrschog - wyoohmpgug) View more |